针对非切除肝脏疾病的不同放射治疗方式的剂量比较
Cas Stefaan Dejonckheere1, Mateusz Bilski2,3,4, Younèss Nour1
1Department of Radiation Oncology, University Hospital Bonn 53127 Bonn, Germany.
Clinical and translational radiation oncology
|March 27, 2025
概括
千伏电子支臂疗法 (eBT) 与肝转移的立体体辐射疗法 (SBRT) 相比,可以更好地节省健康的肝脏组织和处于风险中的器官. 然而,SBRT提供更快的治疗和更好的目标覆盖.
科学领域:
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
- 肝胆道手术 肝胆道手术
背景情况:
- 放射治疗越来越多地用于有限的肝转移.
- 存在各种技术方法,需要进行比较分析.
研究的目的:
- 为了进行三种放射治疗方式的剂量比较,用于未切除的肝转移.
- 为了评估健康肝脏组织的暴露,目标体积覆盖,有风险的器官 (OARs) 剂量和治疗时间.
主要方法:
- 一项多中心研究涉及30名患有单一肝转移的患者.
- 间歇性高剂量率支臂疗法 (HDR),立体体辐射疗法 (SBRT) 和千伏电子支臂疗法 (eBT) 的剂量比较,使用25-Gy单片.
- 主要终点:健康的肝脏组织暴露. 二级终点:目标覆盖率,OAR剂量,治疗时间.
主要成果:
- 电子BT (eBT) 显示出明显更好的OAR节约剂量,而不是SBRT.
- 与SBRT相比,健康肝脏的辐射暴露在eBT和HDR中明显较低 (p < 0.001).
- 与HDR和eBT (p < 0.001) 相比,SBRT的平均治疗时间最短 (6.1分钟) 和PTV覆盖率最高 (D90%,D95%).
结论:
- 最少侵入性单导管eBT是一种针对不可切除的肝转移的新方法,提供了优秀的OAR节约性但低于最佳的目标覆盖.
- 类似于HDR的多个居住的eBT方法可以通过优化目标覆盖率,同时保持OAR节省来提高临床适用性.
- 需要进一步的前性研究来确定eBT在肝脏导向治疗中的作用.
相关概念视频
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...


